
DiaMedica Therapeutics DMAC
$ 9.4
0.7%
Quarterly report 2025-Q3
added 11-12-2025
DiaMedica Therapeutics DSO Ratio 2011-2025 | DMAC
Annual DSO Ratio DiaMedica Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 569 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 569 | 569 | 569 |
Quarterly DSO Ratio DiaMedica Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 142 | 142 | 142 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
132 | $ 220.27 | 4.81 % | $ 5 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.28 | -2.28 % | $ 609 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.3 | -3.51 % | $ 7.94 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
Aptorum Group Limited
APM
|
20.6 | $ 1.29 | -3.01 % | $ 7.03 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.75 | 1.61 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.26 | -3.12 % | $ 252 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 25.27 | -2.43 % | $ 1.22 B | ||
|
Anika Therapeutics
ANIK
|
77.3 | $ 9.57 | 0.84 % | $ 140 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | ||
|
Axon Enterprise
AXON
|
134 | $ 566.18 | -2.56 % | $ 42.9 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
150 | $ 2.34 | 2.59 % | $ 14.7 M | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 11.54 | 0.87 % | $ 746 M | ||
|
Biogen
BIIB
|
57.9 | $ 174.42 | 1.11 % | $ 25.4 B | ||
|
Abeona Therapeutics
ABEO
|
387 | $ 5.36 | -2.99 % | $ 115 M | ||
|
Dynavax Technologies Corporation
DVAX
|
56.5 | $ 10.85 | -0.14 % | $ 1.41 B | ||
|
ADiTx Therapeutics
ADTX
|
621 | $ 2.3 | -3.0 % | $ 30.3 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Фармсинтез
LIFE
|
209 | - | - | - | ||
|
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M |